Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

David S. Hong(The University of Texas MD Anderson Cancer Center), Marcus O. Butler(University of Toronto)
Nature Medicine
January 1, 2023
10.1038/s41591-022-02128-z
Cited by 185

Related Papers

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2019|88
Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help
|PLoS ONE|2012|41
ELECTRONIC SUPPLEMENTARY MATERIAL―Online Only from Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
|Unknown|2023|0